Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Benefits of the Intermittent Use of 6-Mercaptopurine and Methotrexate in Maintenance Treatment for Low-Risk Acute Lymphoblastic Leukemia in Children: Randomized Trial From the Brazilian Childhood Cooperative Group Protocol ALL-99

Full text
Author(s):
Show less -
Brandalise, Silvia R. [1] ; Pinheiro, Vitoria R. ; Aguiar, Simone S. ; Matsuda, Eduardo I. ; Otubo, Rosemary ; Yunes, Jose A. ; Pereira, Waldir V. ; Carvalho, Eny G. ; Cristofani, Lilian M. ; Souza, Marcelo S. ; Lee, Maria L. ; Dobbin, Jane A. ; Pombo-de-Oliveira, Maria S. ; Lopes, Luiz F. ; Melnikoff, Katharina N. T. ; Brunetto, Algemir L. ; Tone, Luiz G. ; Scrideli, Carlos A. ; Morais, Vera L. L. ; Viana, Marcos B.
Total Authors: 20
Affiliation:
[1] Univ Estadual Campinas, Serv Hematol Oncol Pediat, BR-13083970 Campinas, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Journal of Clinical Oncology; v. 28, n. 11, p. 1911-1918, APR 10 2010.
Web of Science Citations: 45
Abstract

Purpose To describe event-free survival (EFS) and toxicities in children with low-risk acute lymphoblastic leukemia (ALL) assigned to receive either continuous 6-mercaptopurine (6-MP) and weekly methotrexate (MIX) or intermittent 6-MP with intermediate-dose MTX, as maintenance treatment. Patients and Methods Between October 1, 2000, and December 31, 2007, 635 patients with low-risk ALL were enrolled onto Brazilian Childhood Cooperative Group for ALL Treatment (GBTLI) ALL-99 protocol. Eligible children (n=544) were randomly allocated to receive either continuous 6-ME/MIX (group 1, n 272) or intermittent 6-MP (100 mg/m(2)/d for 10 days, with 11 days resting) and MIX (200 mg/m(2) every 3 weeks; group 2, n = 272). Results The 5-year overall survival (OS) and EFS were 92.5% +/- 1.5% SE and 83.6% +/- 2.1% SE, respectively. According to maintenance regimen, the OS was 91.4% +/- 2.2% SE (group 1) and 93.6% +/- 2.1% SE (group 2; P=.28) and EFS 80.9% +/- 3.2% SE (group 1) and 86.5% +/- 2.8% SE (group 2; P=.089). Remarkably, the intermittent regimen led to significantly higher EFS among boys (85.7% v 74.9% SE; P=027), while no difference was seen for girls (87.0% v 88.8% SE; P=.78). Toxic episodes were recorded in 226 and 237 children, respectively. Grade 3 to 4 toxic events for groups 1 and 2 were, respectively, 273 and 166 for hepatic dysfunction (P=.002), and 772 and 636 for hematologic episodes (P=.005). Deaths on maintenance were: seven (group 1) and one (group 2). Conclusion The intermittent use of 6-MP and MIX in maintenance is a less toxic regimen, with a trend toward better long-term EFS. Boys treated with the intermittent schedule had significantly better EFS. (AU)

FAPESP's process: 01/13206-9 - Gene expression profiles associated with chemotherapy in acute lymphoid leukemia of childhood
Grantee:Luiz Gonzaga Tone
Support type: Genome Research Grants